Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Executive Summary
Larger of two doses of the NGF inhibitor hit two efficacy endpoints, but the rate of joint health outcomes on a composite measure was higher than control by a statistically significant margin.
You may also be interested in...
Keeping Track: Aimmune’s Peanut Allergen Approved; Novartis’ Inclisiran, Pfizer/Lilly’s Tanezumab, Bayer’s Nifurtimox Submitted
Highlights of the latest drug development news from our US FDA Performance Tracker.
Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions
The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.
Shaw Leaves Lilly To Helm Gilead’s Kite
After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.